Poster Session - Day 2
Preparing and Presenting your poster:
- Please make the dimensions of your poster no larger than 4’ high X 6’ long.
- Pushpins and Velcro will be available.
- Presenters are requested to stay near their posters during the poster session to field questions and discuss their findings.
POSTER SESSION - DAY 2, October 9, 2024
Abstract/ | Name | Title |
2 | Daley, Brianna | SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma |
4 | Yavuz, Bengi Ruken | Anticancer Target Combinations: A Network-Informed Signaling-Based Approach to Discovery |
8 | Messing, Simon | Improved Production of Class I Phosphatidylinositol 4,5-bisphosphate 3-kinase |
10 | Shukla, Hem | synergistic interaction of HIf1α and KRAS leads to tumor aggression and radiation resistance in pancreatic cancer |
12 | Wang, Junwei | ADT-007, a 1st-in-class pan-RAS inhibitor with a unique mechanism of RAS selectivity |
14 | Ongey, Elvis | Biochemical and mechanistic insights into NRas depalmitoylation by ABHD17 |
16 | Nuevo Tapioles, Cristina | BIRC6 Ubiquitinates KRAS4A |
18 | Finniff, Bridget | Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers |
20 | Martinez, Orlando | Investigating RAS guanine nucleotide exchange factor SOS1 negative feedback regulation by RSK1-mediated 14-3-3 association |
22 | Xu, Liang | Allosteric Modulation of NF1 GAP Activity |
24 | Timar, Jozsef | Farnesyltransferase inhibitors potentiate antitumoral effects of mutant KRAS inhibitors in preclinical models of cancers |
26 | Vena, Francesca | Characterization of a Panel of CRISPR/Cas9 Engineered KRAS G12C Inhibitor-resistant Tumor Models |
28 | Ackermann, Sarah | Identifying Metabolic Requirements for RAS Inhibitor Resistance in Pancreatic Cancer |
30 | Whitley, Matthew | Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties |
32 | Stephen, Andy | RRAS2 allosterically regulates SOS. |
34 | Mundra, Surbhi | Characterization of Kinetic and Redox Properties of Oncogenic KRASG12C Inhibitors |
38 | Ozawa, Hiroki | KRAS Mutant Lung and Pancreatic Cancers are Dependent on MUC1-C for Resistance to KRAS Inhibitors |
42 | Todd, Haley | CK2-dependent MYC phosphorylation regulates MYC protein stability and response to KRAS inhibition in pancreatic cancer |
44 | Mukherjee, Priyanjali | Post-transcriptional Control of SRSF9 Promotes the Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cells |
48 | Molina-Arcas, Miriam | Investigating therapeutic strategies to overcome development of resistance to KRASG12C inhibitors and enhance anti-tumour immunity |
50 | Araki, Toshiyuki | Structure-function analysis in mice unexpectedly reveals that SHP2 catalytic activity is dispensable for early mouse development and RAS activation by EGFR and FGFR. |
52 | Borthakur, Gautam | Targeting ERK1/2 in Acute Myeloid Leukemia: Impact on Mitochondrial Dynamics to Overcome Resistance |
54 | Mira, Alessia | EML4-ALK mediates resistance to KRAS G12C inhibition |
56 | Frone, Megan | RNA studies and somatic second hit data clarify classification of a RASA1 intronic variant in a patient with capillary malformation-arteriovenous malformation syndrome with Parkes Weber phenotype |
58 | Drizyte-Miller, Kristina | Combination of MTA-Cooperative PRMT5 Inhibitor MRTX1719 and KRAS Inhibitors for the Treatment of MTAP-Deficient KRAS-Mutant Pancreatic Cancer |
60 | Degan, Seamus | Characterization of the ULK-Regulated Proteome in KRAS-driven Pancreatic Cancer |
62 | Hibshman, Priya | Defining the role of MYC in KRAS-mutant pancreatic cancer |
64 | Kim, Hyungdong | Translation initiation factor eIF2B is essential for the stimulation of SOS:mutant KRAS function and LUAD tumorigenesis. |
66 | Huang, Chunghui | Robust antitumor activity in mouse pancreatic cancer models of an orally bioavailable prodrug of ADT-007, a 1st-in-class pan-RAS inhibitor. |
68 | Tan, Stanley | Testing receptor desolvation scoring for molecular docking to RAS proteins |
70 | Andrade Bonilla, Pedro | Live cell FLIM-FRET investigation highlights differential interaction of RAS oncogenes with plasma membrane lipids. |
72 | Downward, Julian | Development and Characterization of Covalent Inhibitors of the RAS-PIK3CA interaction |
74 | Chakrabarti, Mayukh | Generative Molecular Design: Application of an in-silico molecular generation pipeline towards the discovery of potential RAS therapeutics |
76 | Fields, Kristie | Increasing Cancer Clinical Trial Participation in Underserved Communities |
78 | Guterres, Adam | SNP-specific CRISPR: Uncovering EphA2 and DUSP4 as therapeutic vulnerabilities in NRAS-mutant melanoma |
80 | Yohe, Marielle | Echocardiographic and behavioral analysis of adult Mek1(Y130C) mice |
82 | Yohe, Marielle | Functional characterization of novel germline HRAS variants |
84 | Solanki, Hitendra | Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven by KRASG12C amplification or NRASG13R mutation |
86 | Taylor, Khalilah | Elucidation of Novel Avutometinib-Anchored Inhibitor Combinations for Pancreatic Cancer |
88 | Columbus, John | Development of a high-throughput cell-based assay to interrogate RAS-lipid interactions |
90 | Messerli, Shanta | Evaluating Macromolecular Antioxidants for Reducing Chemotherapy-Induced Adverse Events and Modulating Tumor Progression in a Metastatic Triple-Negative Breast Cancer Mouse Model |
92 | DeLiberty, Jonathan | PIKfyve Inhibition Enhances the Efficacy of RAS-ERK MAPK Inhibitors in Pancreatic Cancer |
94 | Kabiri, Zahra | KRAS G12V Mutation Is Associated with Better Prognostic Advantage in Early-Stage Pancreatic Ductal Adenocarcinoma. |
96 | Bishop, Cassie | Presentation Title: Loss of the UBE2F-CUL5 axis mediates resistance to KRAS inhibition in pancreatic cancer |
104 | Mukti, Roushney Fatima | Role of RAS Nanoclustering in the Activation of RAL By RALGDS |
106 | Neumann, Jacob (withdrawn) | Survivin Promotes the Warburg Effect in KRAS-dependent Cancer Cells by Interacting with a Key Metabolic Enzyme |
108 | Lieschke, Elizabeth | Diacylglycerol kinase inhibition improves treatment response in KRAS mutant lung cancer |
110 | Kato, Ryoji | In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C-mutant non–small cell lung cancer |
114 | Gulay, Kevin Christian | Understanding MRTX1133 Resistance in Pancreatic Cancer: The Role of Tumor Microenvironment Modulation in Developing Alternative Therapeutic Strategies |
116 | Gitego, Nadege | BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRASG12D and KRASG12V preclinical models |
118 | Stern, Yaakov | Targeting CDK12/13 overcomes acquired resistance to KRASG12C inhibitors in NSCLC |
120 | Xing, Bowen | RAB27B Controls NRAS Activity, Trafficking, and Stability in Acute Myeloid Leukemias |
122 | Stamey, Addison | Overcoming KRASG12D inhibitor resistance in pancreatic ductal adenocarcinoma: insights from KEAP1-driven mechanisms and combination therapy approaches |
124 | Esposito, Dom | Receptor tyrosine kinases may play a dual positive and negative regulatory role in RAS-MEK-ERK signaling |
126 | Hook, Sara | Building High-Performing R&D Cultures and Empowering the Next Generation of Scientific Leaders |
P2 | Dash, Subhra | Investigating mechanisms responsible for MAP kinase pathway resistance in RAS-altered Neuroblastoma cells. |
P4 | Odeniyide, Patience | Combined inhibition of farnesyltransferase and MEK inhibits growth and promotes myogenic differentiation in HRAS-mutant rhabdomyosarcoma |
P6 | Bialousow, Lucas | PTEN oxidation drives elevated PI3K signaling in KRAS driven PDAC |
P8 | Vaseva, Angelina | Evaluation of the RAF/MEK Clamp Avutometinib in RAS-driven Rhabdomyosarcoma |
P10 | Stronach, Beth | Unmet Needs in the RASopathies |
P12 | Farouk Sait, Sameer | Hydroxychloroquine prevents resistance and potentiates antitumor effect of SHP2 inhibition in NF1-associated Malignant Peripheral Nerve Sheath Tumors |